Invention Grant
- Patent Title: Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
-
Application No.: US16347849Application Date: 2017-11-07
-
Publication No.: US11014922B2Publication Date: 2021-05-25
- Inventor: Pratik Devasthale , Fang Moore , Guohua Zhao , Susan Nicole Pieniazek , Kumaravel Selvakumar , Suresh Dhanusu , Manoranjan Panda , Lawrence R. Marcin
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agent Gary Greenblatt
- International Application: PCT/US2017/060383 WO 20171107
- International Announcement: WO2018/089355 WO 20180517
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/4375 ; A61P1/16 ; A61P13/12 ; A61P11/00 ; A61P35/00

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
Public/Granted literature
- US20190270741A1 CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS Public/Granted day:2019-09-05
Information query